Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, General Biologicals's Enterprise Value is NT$2,599.9 Mil.
General Biologicals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-302.8 Mil. Therefore, General Biologicals's EV-to-FCF for today is -8.59.
The historical rank and industry rank for General Biologicals's EV-to-FCF or its related term are showing as below:
ROCO:4117'
s EV-to-FCF Range Over the Past 10 Years
Min: -1461.64 Med: -7.87 Max: 178.52
Current: -8.59
During the past 13 years, the highest EV-to-FCF of General Biologicals was 178.52. The lowest was -1461.64. And the median was -7.87.
ROCO:4117's EV-to-FCF is ranked worse than 100% of 565
companies
in the Drug Manufacturers industry
Industry Median: 20.96
vs ROCO:4117: -8.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
General Biologicals (ROCO:4117) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
General Biologicals's PE Ratio (TTM) for today is calculated as:
General Biologicals's share price for today is NT$10.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$7.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
General Biologicals EV-to-FCF Related Terms
General Biologicals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for General Biologicals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
General Biologicals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, General Biologicals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where General Biologicals's EV-to-FCF falls into.
General Biologicals's current Enterprise Value is NT$2,599.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. General Biologicals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-302.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
General Biologicals (ROCO:4117) has a EV-to-FCF of -8.59 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on General Biologicals and its competitors. According to the industry distribution chart, General Biologicals ranks #999999 out of 565 companies in the Drug Manufacturers industry.
Is General Biologicals' EV-to-FCF too high?
General Biologicals' current EV-to-FCF is -8.59. Based on the distribution chart, General Biologicals ranks #999999 out of 565 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, General Biologicals ranks #999999 out of 565 companies for EV-to-FCF. This places General Biologicals in the lower half of its industry. The industry median EV-to-FCF is 20.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on General Biologicals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current EV-to-FCF is -8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.06, compared to a current price of NT$10.40 — trading 26% below its estimated fair value. The current EV-to-FCF is -8.59. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current EV-to-FCF is -8.59 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is General Biologicals (ROCO:4117) Overvalued in 2026?
Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued.
The current stock price of NT$10.40 is trading 26% below its estimated GF Value™ of NT$14.06.
GuruFocus considers General Biologicals to be Modestly Undervalued.
Key valuation signals for ROCO:4117:
EV-to-FCF: -8.59
GF Value™: NT$14.06 vs. price of NT$10.40 (26% below fair value)
No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score
Get the complete analysis for ROCO:4117
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4117 has been successfully added to your 
